PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Case Inclusion Criteria * Any gender, race, or ethnicity is acceptable * Must be at least 18 years of age * All subjects must fall into the following group: All Cases will be classified as following cohorts Cohort lung cancer - Subject must meet the following criteria: * Recently diagnosed advanced lung cancer * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable) and/or on treatment * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Gyn malignancies (list ovarian and uterine cancer separately) * Recently diagnosed advanced gynecological malignancies * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Gastrointestinal malignancies Cohort (list all cancers separately-colorectal, gastric, esophageal and pancreatic) * Recently diagnosed advanced gastrointestinal malignancy * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Melanoma Cohort * Recently diagnosed advanced melanoma * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Breast cancer Cohort * Recently diagnosed advanced breast cancer * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Head and neck cancer Cohort * Recently diagnosed advanced head and neck cancer * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Sarcoma and soft tissue cancer cohort * Recently diagnosed advanced cancer * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Prostate cancer * Recently diagnosed advanced cancer * Locally advanced and metastatic solid tumors * Treatment naïve (not yet treated or tumor removed; biopsy acceptable). * Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing Additional Requirements * Subjects must be diagnosed by appropriate histopathology * Subjects can have any concurrent diseases * Must voluntarily sign and understand the most current Institutional Review Board/Independent Ethics Committee (IRB/IEC) - approved Informed Consent Form (ICF) prior to study participation. Witness must sign the informed consent form if the subject is illiterate. Exclusion Criteria * Subjects incapable of understanding the items listed in the ICF and the consent process * Pregnant females * Subjects with a history of or known psychiatric illness that deems them unable to consent